RO60 and lung disorder: Interestingly, there was no increase in clinical features often associated with anti-SSA/Ro antibodies including mucocutaneous, MSK, neurological or pulmonary disease in C4 compared to other clusters (nor reduced frequency of these features in C2) [53].